Format

Send to

Choose Destination
Exp Hematol. 2015 Sep;43(9):756-9. doi: 10.1016/j.exphem.2015.05.007. Epub 2015 Jul 2.

Two new routes to make blood: Hematopoietic specification from pluripotent cell lines versus reprogramming of somatic cells.

Author information

1
Department of Molecular Medicine, Lund Stem Cell Center, Lund University, Lund, Sweden. Electronic address: sofie.singbrant@med.lu.se.
2
Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
3
Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, USA.
4
Division of Developmental, Regenerative and Stem Cell Biology & Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
5
Department of Stem Cell and Regenerative Biology, Harvard University, Harvard Medical School, Program in Cellular and Molecular Medicine, Division of Hematology and Oncology, Boston Children's Hospital, Harvard Stem Cell Institute, Cambridge, MA, USA.
6
Stem Cell Transplantation Program, Division of Hematology and Oncology, Boston Children's Hospital, Harvard Medical School, Harvard Stem Cell Institute, Cambridge, MA, USA.

Abstract

Transplantation of hematopoietic stem cells (HSCs) to treat hematologic disorders is routinely used in the clinic. However, HSC therapy is hindered by the requirements of finding human leukocyte antigen (HLA)-matched donors and attaining sufficient numbers of long-term HSCs in the graft. Therefore, ex vivo expansion of transplantable HSCs remains one of the "holy grails" of hematology. Without the ability to maintain and expand human HSCs in vitro, two complementary approaches involving cellular reprogramming to generate transplantable HSCs have emerged. Reprogrammed HSCs represent a potentially inexhaustible supply of autologous tissue. On March 18th, 2015, Dr. George Q. Daley and Dr. Derrick J. Rossi, two pioneers in the field, presented and discussed their most recent research on these topics in a webinar organized by the International Society for Experimental Hematology (ISEH). Here, we summarize these seminars and discuss the possibilities and challenges in the field of hematopoietic specification.

PMID:
26143581
DOI:
10.1016/j.exphem.2015.05.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center